InVivos Jason Fowler Wins 2012 Ironman World Championship

pan>)--InVivo Therapeutics Holdings Corp. (NVIV), a developer of
groundbreaking technologies for the treatment of spinal cord injuries
(SCI) and other neurotrauma conditions, today congratulates InVivo
Therapeutics sponsored athlete Jason Fowler on winning the 2012 Ironman
70.3 World Triathlon Championships in Las Vegas, NV.
“Jasons commitment to his sport is only exceeded by his commitment to
the spinal cord injury community”
As a nationally ranked amateur motocross racer, Fowler was paralyzed
from the chest down at the age of 17 as the result of a motorcycle
accident. Following his accident Fowler remained an avid athlete, and
has since completed 150 road races, 30 marathons, and 29 triathlons, and
has won several local and national competitions including two World
Championships. He also regularly volunteers his time to traumatically
injured children and trains aspiring athletes.
Most recently, Fowler took first place in the 2012 Ironman 70.3 World
Triathlon Championships in Las Vegas, NV. As a triathlete, Fowler
competes conventionally in the swim and participates in the bike ride
stage using a handcycle, and in the run portion using a racing
wheelchair. Remarkably, the entire distance of the race is covered using
only the strength and endurance of the upper body.
Jasons commitment to his sport is only exceeded by his commitment to
the spinal cord injury community, said Frank Reynolds, InVivo Chief
Executive Officer. We all know the importance of first responders at
any emergency, but well after the doctors, nurses, and rehabilitation
experts finish their work, Jason and his team at the Boston Chapter of
the National Spinal Cord Injury Association arrive to teach patients how
to adjust and adapt to a new set of possibilities for their lives. Jason
is a Ironnman in every sense of the word.
To read more and see a great video about Jason, please visit: www.jasonfowlerracing.com/
and http://boston.cbslocal.com/2012/12/05/paraplegic-athlete-from-belmont-cr....
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform
technology to develop treatments to improve function in individuals
paralyzed from traumatic spinal cord injuries. The company was founded
in 2005 based on proprietary technology co-invented by Robert S. Langer,
ScD. Professor at Massachusetts Institute of Technology, and Joseph P.
Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In
2011, the company earned the prestigious 2011 David F. Apple Award from
the American Spinal Injury Association for its outstanding contribution
to spinal cord injury medicine. The publicly traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Certain statements contained in this press release that are not
historical facts may constitute forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities and Exchange Act of 1934, and the Company intends that
such statements are subject to the safe harbor created thereby. These
statements include, but are not limited to, those relating to the
expected approval of the FDA to conduct human clinical trials for the
Companys products, the expected commencement date of any approved human
clinical trials, the expected size of the pilot study, the expectation
that the scaffold product will be regulated under a HDE pathway, and the
expected acceleration of commercialization of the Companys products
resulting therefrom. These forward-looking statements are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not limited
to, risks and uncertainties relating to the Companys ability to obtain
FDA approval to conduct human clinical trials; whether the human
clinical trials produce acceptable results; the Companys ability to
develop, market and sell products based on its technology; the expected
benefits and efficacy of the Companys products and technology in
connection with spinal cord injuries; the availability of substantial
additional funding for the Company to continue its operations and to
conduct research and development, clinical studies and future product
commercialization; and, the Companys business, research, product
development, regulatory approval, marketing and distribution plans and
strategies. These and other factors are identified and described in more
detail in our Annual Report on Form 10-K for the year ended December 31,
2011 and subsequent filings with the SEC.
Forward-looking statements contained in this press release speak only as
of the date of this release. Subsequent events or circumstances
occurring after such date may render these statements incomplete or out
of date. The Company undertakes no obligation and expressly disclaims
any duty to update such statements.

Information Source: Business Wire